Shield Therapeutics shares pressured by legal worries

0 mins. to read
Shield Therapeutics shares pressured by legal worries
Master Investor Magazine

Never miss an issue of Master Investor Magazine – sign-up now for free!

Read the latest Master Investor Magazine

AIM-listed pharmaceutical firm Shield Therapeutics (LON:STX) has seen its share price drop by 3.55% to 109.55p (as of 13:05 BST) after legal proceedings were lodged against it. Teva Pharmaceuticals has filed an appeal to the Opposition Division of the European Patent Office regarding the decision on a patent held by Shield.

Management said that the company will defend its intellectual property and believe that the board of appeal should uphold the original decision.

On 30th July at 1pm we’ll be holding the next live Q&A webinar with the Master Investor himself, Jim Mellon. Please share a question for Jim below and we’ll try to answer as many as possible in the live webinar. Sign up for the webinar here.

Are you interested in joining Jim's webinar?

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *